US2012244221A1PendingUtilityA1

Extended-release formulation for reducing the frequency of urination and method of use thereof

47
Assignee: DILL DAVID APriority: Jul 8, 2010Filed: Jun 4, 2012Published: Sep 27, 2012
Est. expiryJul 8, 2030(~4 yrs left)· nominal 20-yr term from priority
Inventors:David A. Dill
A61P 7/10A61P 7/12A61K 31/122A61P 25/14A61K 31/4025A61K 31/167A61K 31/216A61K 31/4725A61K 9/2846A61K 9/2866A61K 31/46A61K 31/405A61K 31/616A61K 31/136A61K 45/06A61P 29/00A61K 31/192A61K 9/284
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.

Claims

exact text as granted — not AI-modified
1 . A method for reducing the frequency of urination, comprising:
 administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising:
 a first analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, 
 wherein said pharmaceutical composition is formulated in an extended-release formulation and wherein said first analgesic agent is administered orally at a daily dose of 5 mg to 2000 mg. 
   
     
     
         2 . The method of  claim 1 , wherein said first analgesic agent is administered orally at a daily dose of 50 mg to 500 mg. 
     
     
         3 . The method of  claim 2 , wherein said first analgesic agent is administered orally at a daily dose of 100 mg to 500 mg. 
     
     
         4 . The method of  claim 3 , wherein said first analgesic agent is administered orally at a daily dose of 250 mg to 500 mg. 
     
     
         5 . The method of  claim 1 , wherein said first analgesic agent is administered orally at a daily dose of 250 mg to 1000 mg. 
     
     
         6 . The method of  claim 1 , wherein said pharmaceutical composition is formulated in an extended-release formulation by embedding said first ingredient in a matrix of insoluble substance(s). 
     
     
         7 . The method of  claim 1 , wherein said pharmaceutical composition is formulated in an extended-release formulation comprises a polymer controlling release by dissolution controlled release. 
     
     
         8 . The method of  claim 1 , wherein said pharmaceutical composition is formulated in an extended-release formulation comprises a water soluble or water-swellable matrix-forming polymer. 
     
     
         9 . The method of  claim 1 , wherein said extended-release formulation is coated with an enteric coating. 
     
     
         10 . The method of  claim 1 , wherein said pharmaceutical composition further comprises a second analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, wherein said second analgesic agent is different from said first analgesic agent and wherein said second analgesic agent is administered orally at a daily dose of 5 mg to 2000 mg. 
     
     
         11 . The method of  claim 10 , wherein n said second analgesic agent is administered orally at a daily dose of 50 mg to 500 mg. 
     
     
         12 . The method of  claim 11 , wherein said first analgesic agent is administered orally at a daily dose of 100 mg to 500 mg. 
     
     
         13 . The method of  claim 12 , wherein said first analgesic agent is administered orally at a daily dose of 250 mg to 500 mg. 
     
     
         14 . The method of  claim 10 , wherein said second analgesic agent is administered orally at a daily dose of 250 mg to 1000 mg. 
     
     
         15 . The method of  claim 1 , wherein said pharmaceutical composition further comprises an antimuscarinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine. 
     
     
         16 . The method of  claim 1 , wherein said pharmaceutical composition further comprises one or more antidiuretic agents. 
     
     
         17 . The method of  claim 1 , wherein said pharmaceutical composition further comprises one or more spasmolytics. 
     
     
         18 . The method of  claim 1 , further comprising:
 administering to said subject a diuretic;   wherein said diuretic is administered at least 8 hours prior to a target time, and wherein said pharmaceutical composition is administered within 2 hours prior to said target time.   
     
     
         19 . A method for reducing the frequency of urination, comprising:
 administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising:
 a first component formulated for immediate-release; and 
 a second component formulated for extended-release, 
 wherein said first component and said second component each comprises one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein each analgesic agent in said first component and said second component is administered orally at a daily dose of 5 mg to 2000 mg. 
   
     
     
         20 . The method of  claim 19 , wherein said second component is coated with an enteric coating. 
     
     
         21 . The method of  claim 19 , wherein each of said analgesic agent in each component is administered orally at a daily dose of 50 mg to 500 mg. 
     
     
         22 . The method of  claim 19 , wherein said first component and/or said second component further comprises an antimuscarinic agent selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine. 
     
     
         23 . The method of  claim 19 , wherein said first component and/or said second component further comprises an antidiuretic agent. 
     
     
         24 . The method of  claim 19 , wherein said first component and/or said second component further comprises one or more spasmolytics. 
     
     
         25 . The method of  claim 19 , further comprising:
 administering to said subject a diuretic;   wherein said diuretic is administered at least 8 hours prior to a target time, and wherein said pharmaceutical composition is administered within 2 hours prior to said target time.   
     
     
         26 . A pharmaceutical composition, comprising:
 one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen;   an antidiuretic agent; and   a pharmaceutically acceptable carrier,   wherein said pharmaceutical composition is formulated for extended-release in an oral dosage form, and wherein the total dosage of said one or more analgesic agents is 5 mg to 1000 mg.   
     
     
         27 . The pharmaceutical composition of  claim 26 , further comprising an antimuscarinic agent. 
     
     
         28 . The pharmaceutical composition of  claim 26 , further comprising a spasmolytic.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.